Quality Improvement Initiative Can Cut NTSV Cesarean Rate

Share this content:
Quality Improvement Initiative Can Cut NTSV Cesarean Rate
Quality Improvement Initiative Can Cut NTSV Cesarean Rate

MONDAY, Jan. 30, 2017 (HealthDay News) -- Quality improvement initiatives, including provider education and feedback, can reduce the nulliparous term singleton vertex (NTSV) cesarean delivery rate, according to a study published in the February issue of The Joint Commission Journal on Quality and Patient Safety.

From 2008 to 2015, Mary A. Vadnais, M.D., M.P.H., from Harvard Medical School in Boston, and colleagues used a multi-center approach that included provider education and feedback and implementation of new policies to target evidence-based and inferred factors that influence the NTSV cesarean delivery rate. Mode of delivery and maternal and neonatal outcomes data were obtained from birth certificates and administrative claims data.

The researchers analyzed more than 20,000 NTSV deliveries, including more than 15,000 during the intervention period. Over eight years, the NTSV cesarean delivery rate decreased from 35 to 21 percent. There was also a decline in the total cesarean delivery rate. There were increases in meconium aspiration syndrome and maternal transfusion.

"Quality improvement initiatives can decrease the NTSV cesarean delivery rate," the authors write. "Any increased incidence of fetal or maternal complications associated with decreased NTSV cesarean delivery rate should be considered in the context of the risks and benefits of vaginal delivery compared to cesarean delivery."

Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »